利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.031 秒)

    ANTIBODIES
    1.
    发明申请
    ANTIBODIES 审中-公开
    抗体

    公开(公告)号：US20120058112A1

    公开(公告)日：2012-03-08

    申请号：US13264595

    申请日：2010-04-06

    申请人： Sriram Sathyanarayanan ,  Shailaja Kashibhatla ,  Christopher Winter ,  Michael Chastain

    发明人： Sriram Sathyanarayanan ,  Shailaja Kashibhatla ,  Christopher Winter ,  Michael Chastain

    IPC分类号： A61K39/395 ,  A61K31/517 ,  A61K31/519

    CPC分类号： A61K45/06 ,  A61K31/517 ,  A61K39/395 ,  A61K2300/00

    摘要： The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours.

    摘要翻译： 描述了IGF-1R拮抗剂如人源化抗体和抗增殖药物的组合。 在优选的实施方案中，本发明描述了IGF-1R抗体和属于EGFR抑制剂类的抗增殖药物的组合，其优选为厄洛替尼。 根据本发明的组合可用于治疗包括IGF-1R和/或EGFR介导的或依赖性肿瘤的肿瘤。

    METHODS FOR THE IDENTIFICATION AND TREATMENT OF PATIENTS SENSITIVE TO ANTI IGF-1R INHBITION THERAPY
    5.
    发明申请
    METHODS FOR THE IDENTIFICATION AND TREATMENT OF PATIENTS SENSITIVE TO ANTI IGF-1R INHBITION THERAPY 有权
    识别和治疗对抗IGF-1R吸入治疗敏感的患者的方法

    公开(公告)号：US20130323232A1

    公开(公告)日：2013-12-05

    申请号：US13512061

    申请日：2010-11-22

    申请人： Sriram Sathyanarayanan ,  Christopher Winter ,  Youyuan Xu

    发明人： Sriram Sathyanarayanan ,  Christopher Winter ,  Youyuan Xu

    IPC分类号： G01N33/68 ,  A61N5/02 ,  A61N5/10 ,  A61N5/06 ,  A61K39/395 ,  A61K45/06

    CPC分类号： G01N33/6893 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/02 ,  A61N5/06 ,  A61N5/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/5044 ,  G01N33/5091 ,  G01N2333/475

    摘要： Disclosed herein are methods of stratifying a patient population into an IGF-1R inhibitor responder or resistant population comprising assaying a sample of cells derived from a patient to determine if a cell from the patient sample is sensitive to treatment with an IGF-1R inhibitor and selecting a patient for treatment with an IGF-1R inhibitor if the cells from the patient are determined to be sensitive. The determination is based upon either the expression levels of wild type LKB1 in the patient sample wherein a low level of expression of the protein or the gene encoding the biomarker protein is predictive of a favorable outcome to an IGF-1R targeted therapy or detecting the presence of a loss of function mutant LKB1 in the sample, wherein presence of the mutant is predictive of a favorable outcome. The presence of the mutant may be accompanied by determining the expression level of IGF-1R in the same sample, wherein a concomitant increase in the level of expression of IGF-1R in addition to detecting the presence of the mutant protein also predicts a favorable outcome to an IGF-1R targeted therapy. Methods of treating a patient are also provided.

    摘要翻译： 本文公开了将患者群体分层为IGF-1R抑制剂应答者或抗性群体的方法，包括测定来自患者的细胞样品，以确定来自患者样品的细胞是否对用IGF-1R抑制剂治疗敏感，并选择 如果来自患者的细胞被确定为敏感的，则用IGF-1R抑制剂治疗的患者。 该测定基于患者样品中野生型LKB1的表达水平，其中蛋白质的低水平表达或编码生物标记蛋白的基因预示出对IGF-1R靶向治疗的有利结果或检测存在 在样品中失去功能突变体LKB1，其中突变体的存在预示了有利的结果。 突变体的存在可以伴随着确定相同样品中IGF-1R的表达水平，其中除了检测突变蛋白的存在之外，IGF-1R的表达水平伴随增加也预示了有利的结果 到IGF-1R靶向治疗。 还提供了治疗患者的方法。